Logo
Euro Gen BPC 157, 5mg

Euro Gen BPC 157, 5mg

Euro-Gen

Research chemical / peptide reagent
  • Supplied and labelled as a research Use Only peptide, not as a medicinal product, medical device, cosmetic or food.
  • Not authorised or licensed by the MHRA, EMA, FDA or other medicines regulators for any therapeutic indication.
  • Use is subject to general chemical and biological safety regulations and institutional governance for laboratory reagents in the jurisdiction where research is conducted.
  • Researchers are responsible for ensuring that any experimental use complies with local laws, institutional ethics approvals and anti Doping regulations where relevant.
Synthetic pentadecapeptide (BPC-157) for in vitro research

Description

Euro-Gen BPC 157, 5mg is a synthetic research peptide supplied as a lyophilised powder in a sealed vial, intended strictly for in vitro testing and laboratory research. BPC-157 (Body Protection Compound 157) is a stable gastric pentadecapeptide – a 15–amino-acid fragment originally isolated from a protein in human gastric juice. It is widely referenced in preclinical literature exploring tissue repair, angiogenesis, gastrointestinal protection, neuroprotection and musculoskeletal healing, although robust human clinical data remain limited. The Euro-Gen product is marketed as a high-purity (>99%) research-grade peptide and is clearly labelled as for research use only, not a drug, food or cosmetic, and not for human or veterinary administration.

Bnefits

  • Provides a defined 5 mg quantity of synthetic BPC-157 peptide for reproducible in vitro and preclinical research.
  • Derived from the C-terminal gastric protein fragment known as Body Protection Compound 157, widely studied in regenerative and cytoprotective research models.
  • Marketed as high-purity (typically >99% by HPLC) research-grade material suitable for analytical, biochemical and cell-based assays.
  • Supplied as a lyophilised powder in a sealed vial to support stability during transport and storage prior to reconstitution.
  • Backed by substantial preclinical literature investigating roles in tissue repair, angiogenesis, gastrointestinal integrity, and neuroprotection, enabling diverse experimental designs.
  • Clearly designated as for research use only, helping laboratories keep strict separation between research reagents and licensed medicinal products.

Indications

  • No approved therapeutic indications; Euro-Gen BPC 157, 5mg is not licensed as a medicine or medical device.
  • Intended exclusively for in vitro and preclinical laboratory research, for example in models of tissue repair, angiogenesis, gastrointestinal barrier function, neuroprotection, or musculoskeletal healing.
  • Suitable as a reference peptide in analytical chemistry, receptor binding, signalling-pathway, and cell-culture experiments involving BPC-157.
  • May be employed in animal research under appropriate institutional ethics approval, where permitted by local regulations, strictly as a research tool compound.
  • Not for human or veterinary injection, ingestion, inhalation, topical application, or any other route of bodily administration.

Composition

  • Active research ingredient: BPC-157 (Body Protection Compound 157), a synthetic pentadecapeptide derived from a gastric protein.
  • Amino-acid sequence (one-letter code): GEPPPGKPADDAGLV (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val).
  • Empirical (molecular) formula: C62H98N16O22.
  • Molecular weight: approximately 1419.5 g/mol.
  • CAS Registry Number: 137525-51-0.
  • Supplied as lyophilised (freeze-dried) peptide powder; any trace excipients used in lyophilisation are not typically specified and may vary by batch.
  • No solvent, buffer, bacteriostatic agent or diluent is supplied within the vial; these are provided separately by the end user as required for research protocols.

Formulation

  • Lyophilised synthetic peptide powder in a sterile, sealed glass vial containing a nominal 5 mg of BPC-157.
  • Research-grade purity (typically >99% by HPLC according to supplier data) suitable for in vitro assays and preclinical investigations.
  • Intended to be reconstituted using a suitable laboratory-grade diluent (e.g. bacteriostatic water, sterile saline, or assay buffer) by qualified personnel, following institutional SOPs.
  • Formulated and labelled solely as a research reagent; not formulated to meet pharmaceutical standards for human or veterinary administration.

Packaging

  • Single 5 mg BPC-157 lyophilised peptide vial labelled with product name (Euro-Gen BPC 157, 5mg), brand, nominal content and research-use-only disclaimer.
  • Vial closure system typically comprises a rubber stopper and crimped cap to maintain integrity until first puncture.
  • Shipped in protective secondary packaging (e.g. cardboard carton or padded container) to reduce risk of breakage and environmental stress during transit.
  • Accompanied by online product information including overview of BPC-157, structural details, key research themes, and an explicit statement that the product is for in vitro testing and laboratory research only.

Usage

  • For in vitro testing and laboratory research use only; to be handled exclusively by suitably qualified and authorised personnel in an appropriate laboratory environment.
  • Do not use in humans or animals by any route of administration (injection, ingestion, inhalation, topical application, or otherwise); any bodily introduction is expressly prohibited by the supplier.
  • Store and handle the vial under appropriate laboratory conditions; before use, visually check that the lyophilised cake appears intact and that the vial and closure are undamaged.
  • When ready for experimental use, reconstitute the peptide with an appropriate sterile, laboratory-grade diluent according to your institution’s SOPs and the requirements of the planned experiment (e.g. desired concentration and buffer conditions).
  • Use aseptic technique when reconstituting and withdrawing solutions, to avoid contamination and maintain experimental reliability.
  • Record batch number, reconstitution details (diluent, final concentration, date) and storage conditions in laboratory documentation to ensure traceability.
  • Dispose of any unused reconstituted peptide, empty vials, and contaminated materials as chemical/biological laboratory waste in line with institutional and regulatory requirements.
  • Do not rely on marketing or online information as medical guidance; BPC-157 remains an investigational research peptide and is not approved for therapeutic use.

Contraindications

  • Any use involving administration to humans or animals (e.g. via injection, ingestion, inhalation, or topical application) is contraindicated and lies outside the stated purpose of the product.
  • Should not be used as a substitute for any licensed medicinal product, regenerative therapy, or approved medical treatment.
  • Contraindicated in laboratories that cannot provide appropriate containment, personal protective equipment, waste disposal and record-keeping for handling synthetic peptides.
  • Laboratory staff with known hypersensitivity to peptides or specific excipients should minimise exposure, use suitable PPE, and follow occupational-health guidance.
  • Not to be used in doping, performance enhancement, or any context seeking to circumvent anti-doping regulations in sport or competition.

Adverse Effects

  • No formal adverse-effect profile is established for this commercial preparation in humans or animals, as it is not intended for administration.
  • Accidental exposure (e.g. skin or eye contact, inhalation of dust or aerosol, or inadvertent ingestion) may cause non-specific irritation or sensitisation; standard laboratory first-aid measures (rinsing, seeking medical evaluation) should be followed.
  • Unauthorised self-administration or off-label clinical use of research-grade BPC-157 may carry unpredictable risks, including contamination issues, dosing errors, unknown long-term safety, and potential interactions with other substances; such practices are strongly discouraged and outside the intended use.
  • Laboratory personnel should consult institutional safety data and risk assessments for peptides and follow all relevant guidelines to minimise exposure.

Storage Conditions

  • Store unopened vials in a cool, dry place, protected from direct light and moisture, following any specific temperature guidance provided by the supplier (commonly refrigerated or frozen for long-term stability).
  • Avoid repeated temperature cycling and exposure to excessive heat; do not use if the vial is cracked, the seal compromised, or the contents show signs of degradation.
  • After reconstitution, store aliquots according to institutional SOPs (e.g. refrigerated at 2–8 °C for short-term use or frozen at ≤ −20 °C for longer-term storage) and avoid repeated freeze–thaw cycles.
  • Keep out of reach of unauthorised personnel and clearly segregated from licensed medicinal products, food and cosmetics.
  • Observe expiry or best-before dates supplied by the manufacturer, and dispose of expired material as laboratory waste in compliance with local regulations.

Duration

Not applicable. Euro-Gen BPC 157, 5mg is not approved for therapeutic use and has no clinically defined treatment duration or dosing regimen; any exposure of humans or animals as a medical intervention would be outside the intended research-only scope.

Onset

Not applicable to clinical outcomes. In experimental contexts, any observed biochemical or physiological effects of BPC-157 depend on the specific in vitro or preclinical model, concentration, exposure time and protocol, and cannot be extrapolated to human therapeutic use.

Browse more Research chemical / peptide reagent

Top Treatments

Top Cities in the UK